

Brinzolamide risks of Stevens-Johnson syndrome (SJS) and toxic epidermal

[EDA performs label update to include the following:](#)

Special warnings and precautions for use

Systemic effects

Sulphonamide inhibitor of carbonic anhydrase and, although administered topically, is absorbed systemically. **The same types of adverse drug reactions that are attributable to sulphonamides may occur with topical administration, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).** At the time of prescription, patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs of serious reactions or hypersensitivity occur, AZOPT should be withdrawn immediately.

Undesirable effects

Skin and subcutaneous tissue disorders	Uncommon: rash, rash maculo-papular, skin tightness Rare: urticaria, alopecia, pruritus generalised Not Known: Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) (see section 4.4), dermatitis, erythema
--	--

References: [EMA \(Click here\)](#)